Excisional surgery for cancer cure: therapy at a cost.
Coffey, J C Wang, J H Smith, M J F Bouchier-Hayes, D Cotter, T G Redmond, H P
Coffey, J C
Wang, J H
Smith, M J F
Bouchier-Hayes, D
Cotter, T G
Redmond, H P
Advisors
Editors
Other Contributors
Date
2012-02-03T15:08:56Z
Date Submitted
Keywords
Other Subjects
Subject Mesh
Chemotherapy, Adjuvant
Humans
Lymphatic Metastasis
Neoplasm, Residual/drug therapy/*pathology
Neoplasms/drug therapy/*pathology/*surgery
Surgical Procedures, Operative/*adverse effects
Humans
Lymphatic Metastasis
Neoplasm, Residual/drug therapy/*pathology
Neoplasms/drug therapy/*pathology/*surgery
Surgical Procedures, Operative/*adverse effects
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Excisional surgery is one of the primary treatment modalities for cancer. Minimal residual disease (MRD) is the occult neoplastic disease that remains in situ after curative surgery. There is increasing evidence that tumour removal alters the growth of MRD, leading to perioperative tumour growth. Because neoplasia is a systemic disease, this phenomenon may be relevant to all patients undergoing surgery for cancer. In this review we discuss the published work that addresses the effects of tumour removal on subsequent tumour growth and the mechanisms by which tumour excision may alter residual tumour growth. In addition, we describe therapeutic approaches that may protect patients against any oncologically adverse effects of tumour removal. On the basis of the evidence presented, we propose a novel therapeutic paradigm; that the postoperative period represents a window of opportunity during which the patient may be further protected against the oncological effects of tumour removal.
Language
eng
Citation
ISSN
1470-2045 (Print)
1470-2045 (Linking)
1470-2045 (Linking)
eISSN
ISBN
DOI
PMID
14662433